Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity

The study investigated the oral absorption of two anti‐fungal agents, fluconazole and itraconazole, under conditions of low intragastric acidity. Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg fluconazole and famotidine. Two oral doses of 40 mg famotidine were used to induce hypochlorhydria. Serum drug concentrations were measured (by high pressure liquid chromatography) for 48 h after a single dose of each anti‐fungal agent. When dosed with famotidine, there was a significant 52.9% decrease of the peak intraconazole concentration (P < 0.011), and a significant 51.1% decrease of the 48‐h integrated serum intraconazole concentration (P= 0.005). Famotidine‐induced hypochlorhydria did not affect the absorption of fluconazole.

[1]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[2]  J. Lesher NEW ANTIFUNGAL AGENTS , 1992, Dermatologic clinics.

[3]  M. Diaz,et al.  Itraconazole in the treatment of coccidioidomycosis. , 1991, Chest.

[4]  D. Denning,et al.  Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. , 1991, Chest.

[5]  J. Morrow Fluconazole: a new triazole antifungal agent. , 1991, The American journal of the medical sciences.

[6]  W. Hendriks,et al.  Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. , 1991, The Netherlands journal of medicine.

[7]  C. Shikuma,et al.  Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. , 1991, Journal of the American Academy of Dermatology.

[8]  F. Barchiesi,et al.  Fluconazole, itraconazole and ketoconazole in-vitro activity. A comparative study. , 1991, Journal of chemotherapy.

[9]  Jerome J. Schentag,et al.  Increased gastric pH and the bioavailability of fluconazole and ketoconazole. , 1991, Annals of Internal Medicine.

[10]  M. Winter,et al.  Fluconazole for oropharyngeal candidiasis in anti‐HIV positive haemophiliacs , 1991, Alimentary pharmacology & therapeutics.

[11]  S. F. Kowalsky,et al.  Fluconazole: a new antifungal agent. , 1991, Clinical pharmacy.

[12]  R. Powles,et al.  The prophylaxis of fungal infections. , 1991, The Journal of antimicrobial chemotherapy.

[13]  R. Hay Antifungal therapy and the new azole compounds. , 1991, The Journal of antimicrobial chemotherapy.

[14]  J. Thorpe,et al.  Effect of Oral Antacid Administration on the Pharmacokinetics of Oral Fluconazole , 1990, Antimicrobial Agents and Chemotherapy.

[15]  G. Cauwenbergh,et al.  Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. , 1990, British journal of clinical practice. Supplement.

[16]  S. Piscitelli,et al.  Fluconazole: A New Triazole Antifungal Agent , 1990, DICP : the annals of pharmacotherapy.

[17]  N. Blatchford Treatment of oral candidosis with itraconazole: a review. , 1990, Journal of the American Academy of Dermatology.

[18]  J. Galgiani Fluconazole, a new antifungal agent. , 1990, Annals of internal medicine.

[19]  S. Mühldorfer,et al.  Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients , 1990, Mycoses.

[20]  A. Brown Overview of fungal infections in cancer patients. , 1990, Seminars in oncology.

[21]  J. D. Lazar,et al.  The clinical pharmacology of fluconazole. , 1990, Seminars in oncology.

[22]  E. Bailey,et al.  The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole , 1990, Pharmacotherapy.

[23]  P. Robinson,et al.  Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. , 1990, Reviews of infectious diseases.

[24]  J. Fay,et al.  High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. , 1990, Seminars in oncology.

[25]  C. Nord,et al.  Oral yeast infections in immunocompromised and seriously diseased patients. , 1990, Acta odontologica Scandinavica.

[26]  K. Brammer Management of fungal infection in neutropenic patients with fluconazole. , 1990, Haematology and blood transfusion.

[27]  R. Pounder,et al.  Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. , 1990, Alimentary pharmacology & therapeutics.

[28]  G. Sarosi Amphotericin B. Still the 'gold standard' for antifungal therapy. , 1990, Postgraduate medicine.

[29]  P. Vanparys,et al.  Toxicological Profile and Safety Evaluation of Antifungal Azole Derivatives , 1989, Mycoses.

[30]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[31]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.

[32]  P. Cohen,et al.  Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[33]  E. Straus,et al.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[34]  R. Pounder,et al.  The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. , 1988, Scandinavian journal of gastroenterology.

[35]  J. Barone,et al.  Effect of food and gastric acidity on absorption of orally administered ketoconazole. , 1988, Clinical pharmacy.

[36]  D. Warnock,et al.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.

[37]  S. D. Roberts,et al.  Behçet's disease presenting as benign intracranial hypertension. , 1986, Postgraduate medical journal.

[38]  R. Pounder,et al.  Effect of oral famotidine on 24-hour intragastric acidity. , 1986, Postgraduate medical journal.

[39]  H. Mann,et al.  Effect of pH on disintegration and dissolution of ketoconazole tablets. , 1983, American journal of hospital pharmacy.

[40]  J. V. D. van der Meer,et al.  The influence of gastric acidity on the bio-availability of ketoconazole. , 1980, The Journal of antimicrobial chemotherapy.

[41]  F. Odds,et al.  Candida and candidosis , 1979 .